Multi-indication Medicines
Multi-indication medicines highlight both the promise of scientific innovation and the need for thoughtful approaches to patient access.
Multi-indication medicines have the potential to transform care by addressing multiple conditions with a single therapy, often leveraging well-understood mechanisms of action and safety profiles. This approach can expand patient access to safe and effective treatment options.
While already common in oncology, multi-indication medicines continue to face significant challenges across the development and access pathway, from regulatory reviews to payer assessments and clinical adoption. As their use expands into other therapeutic areas, such as immunology and inflammation, these challenges are likely to become even more complex.
Timely and coordinated solutions will be essential to unlock the full potential of multi-indication medicines beyond oncology. A proactive, multi-stakeholder response is required to ensure these innovations can deliver maximum value for patients, health systems and society.
We have therefore been working on a project to address this topic.
Completed work
Activities to date include:
- Literature review and expert interviews to answer the following research questions:
- What is the key value of multiple indication products recognised in the literature?
- What are the current access policies and regulations for multiple indication products in EU4 + UK?
- What are the key P&R challenges for multiple indication products currently experienced in EU4 + UK in practice, within the existing policy systems?
- What are the recommended best practices / potential solutions?
- Wider engagement through a panel and stakeholder engagement with ~800 participants at ISPOR Europe 2024
Disclaimer: work and deliverables to date have been funded by argenx
Deliverables to date
- ISPOR Europe 2024 panel report – Pricing and reimbursement of multiple indication medicines: Can a balance be found between different stakeholder perspectives to optimise value and access for patients, while ensuring sustainable and affordable innovation?
- Paper – Supporting patients with underserved autoimmune diseases: challenges and opportunities for innovative medicines
- Engagement with Dutch stakeholders – Netherlands specific challenges and solutions
- WODC Europe 2025 panel discussion – Expanding patient access to multi-indication medicines through innovative agreements
Disclaimer: work and deliverables to date have been funded by argenx
Ongoing work
We are working with a team of health economist experts to explore one possible solution, the multi-year, multi-indication (MYMI) agreement, to understand if it provides added benefit for better managing multi-indication medicines.
We have now developed a blueprint for a MYMI-inspired access framework. This framework includes several key pillars and elements that can be applied in different ways to guide the assessment and reimbursement of multi-indication medicines. Importantly, the framework encapsulates various dimensions, including broader financial mechanisms beyond pricing, adjustment of health technology assessment processes, and early access. Download a visual overview of the framework, and download the full blueprint.
We now invite you to complete a short questionnaire on the first version of the MYMI-inspired access framework. Your input will help refine the scope and content of the framework blueprint, and we would greatly appreciate your perspectives.
Disclaimer: work and deliverables to date have been funded by argenx
Invitatition to participate
We are working to collaborate and understand from all stakeholders’ perspectives what feasible solutions for multi-indication medicines could look like. As this work has evolved, we recognise the need to create a wider consortium that can contribute to and help drive the conversation on this important topic.
If you would like to be kept updated, collaborate or express interest as an industry sponsor, please visit: